RefleXion Medical, a leader in external-beam theranostic oncology, has announced that researchers will present pioneering scientific findings in 37 oral and poster presentations at the 2024 American Association of Physicists in Medicine (AAPM) Annual Meeting in Los Angeles, July 21-25. These presentations will showcase the efficacy and feasibility of the RefleXion® X1 machine with SCINTIX® biology-guided radiotherapy (BgRT).
“Our research underscores the collaborative effort between physicists, clinicians, and researchers, demonstrating significant advancements in SCINTIX therapy for improving patient care,” stated Sean Shirvani, M.D., chief medical officer of RefleXion.
The presentations will highlight innovative research topics including optimizing multi-target treatment planning, clinical workflow nuances, and the accuracy of SCINTIX therapy. Notably, the introduction of BIGSTAR (Biological Image Guidance for Spatial-Temporally Adaptive Radiotherapy) aims to enhance cancer management by adapting radiotherapy based on real-time tumor biology and immune response.
Key oral presentations and invited programs include:
- Oral: Initial Dosimetric Performance of Multi-Target, Multi-Treatment Area Image-Guided Radiotherapy in a Single Session by Mason Hazlett, M.S.
- Invited Program: PET Guided Radiation Therapy 101 by Dae Yup Han, Ph.D.
- Invited Program: Introduction and Overview of Current Technology for Biology-guided RT by Dae Yup Han, Ph.D.
- Oral: Pulsar – Optimizing Immuno-Radiotherapy Based on Intra-Fraction Immune Response by Robert Timmerman, M.D.
Additionally, RefleXion will host an industry lunch symposium and interactive SCINTIX technology demonstrations at booth #1407. These sessions will feature insights from physicists on clinical experiences, early cases, and Quality Assurance (QA) practices with SCINTIX therapy.
RefleXion Medical, headquartered in Hayward, Calif., specializes in SCINTIX biology-guided radiotherapy, a groundbreaking approach using real-time biological signals to guide radiotherapy delivery for precise tumor targeting. SCINTIX therapy is FDA-cleared for treating lung and bone tumors, both primary and metastatic, using FDG-guided techniques.
